MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$3,433M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
Acquired in-process research and...
Proceeds from debt financing, ne...
In-process research and developm...
Others
Negative Cash Flow Breakdown
Acquisitions, including in-proce...
Net (loss) income
Payments of dividends
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
-
-
2,183
3,052
Net (loss) income
-10,496
2,021
-
-
Depreciation expense
98
93
90
90
Amortization expense
600
596
597
596
Stock-based compensation expense
231
218
230
230
Deferred income taxes
-587
179
-122
659
Net (gain) loss from equity securities
343
142
253
482
Acquired in-process research and development expenses
12,043
107
539
170
In-process research and development impairments
1,750
-
400
0
Other, net
-240
-183
-267
-89
Accounts receivable, net
333
-134
-179
333
Inventories
145
52
123
515
Prepaid expenses and other
13
-5
36
368
Accounts payable
18
-67
-95
230
Income tax assets and liabilities, net
171
-29
-134
-122
Accrued and other liabilities
338
-702
-395
811
Net cash provided by operating activities
3,573
2,544
3,327
4,108
Purchases of marketable debt securities
26
525
1,382
270
Proceeds from sales of marketable debt securities
1,024
2,520
340
219
Proceeds from maturities of marketable debt securities
1
36
23
17
Acquisitions, including in-process research and development, net of cash acquired
11,209
109
609
167
Purchases of equity securities
16
19
14
82
Purchases of property, plant and equipment
140
117
205
147
Other investing activities, net
-20
17
-11
-4
Net cash used in investing activities
-10,347
1,770
-1,835
-427
Proceeds from debt financing, net of issuance costs
4,085
-
0
-
Proceeds from issuances of common stock
9
166
32
97
Repurchases of common stock under repurchase programs
355
419
230
435
Repayments of debt and other obligations
17
2,766
8
9
Payments of dividends
1,029
1,040
994
1,005
Other financing activities, net
-350
-179
-63
-137
Net cash used in financing activities
2,344
-4,239
-1,263
-1,489
Effect of exchange rate changes on cash and cash equivalents
-19
-11
5
-5
Net change in cash and cash equivalents
-4,450
65
233
2,187
Cash and cash equivalents at beginning of period
7,628
7,564
7,926
7,926
Cash and cash equivalents at end of period
3,179
7,628
7,564
7,330
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Acquired in-process
research and development...
$12,043M
(19324.19%↑ Y/Y)
Proceeds from debt
financing, net of issuance...
$4,085M
In-process research and
development impairments
$1,750M
(821.05%↑ Y/Y)
Amortization expense
$600M
(0.33%↑ Y/Y)
Accrued and other
liabilities
$338M
(303.61%↑ Y/Y)
Other, net
-$240M
(-627.27%↓ Y/Y)
Stock-based compensation
expense
$231M
(2.67%↑ Y/Y)
Income tax assets and
liabilities, net
$171M
(113.15%↑ Y/Y)
Depreciation expense
$98M
(5.38%↑ Y/Y)
Accounts payable
$18M
(111.11%↑ Y/Y)
Proceeds from issuances
of common stock
$9M
(-66.67%↓ Y/Y)
Net cash provided by
operating activities
$3,573M
(332.04%↑ Y/Y)
Net cash used in
financing activities
$2,344M
(249.59%↑ Y/Y)
Canceled cashflow
$11,917M
Canceled cashflow
$1,751M
Net change in cash
and cash...
-$4,450M
(-59.90%↓ Y/Y)
Canceled cashflow
$5,917M
Proceeds from sales of
marketable debt securities
$1,024M
(247.12%↑ Y/Y)
Other investing
activities, net
-$20M
(-100.00%↓ Y/Y)
Proceeds from maturities
of marketable debt...
$1M
(-93.33%↓ Y/Y)
Net (loss) income
-$10,496M
Deferred income taxes
-$587M
(-229.78%↓ Y/Y)
Net (gain) loss from
equity securities
$343M
(141.55%↑ Y/Y)
Accounts receivable, net
$333M
(14.04%↑ Y/Y)
Inventories
$145M
(-17.14%↓ Y/Y)
Prepaid expenses and
other
$13M
(116.05%↑ Y/Y)
Payments of dividends
$1,029M
(3.52%↑ Y/Y)
Repurchases of common stock
under repurchase...
$355M
(-32.64%↓ Y/Y)
Other financing
activities, net
-$350M
(-446.88%↓ Y/Y)
Repayments of debt and other
obligations
$17M
(88.89%↑ Y/Y)
Net cash used in
investing activities
-$10,347M
(-388.99%↓ Y/Y)
Canceled cashflow
$1,045M
Effect of exchange rate
changes on cash and cash...
-$19M
(-126.03%↓ Y/Y)
Acquisitions, including
in-process research and...
$11,209M
(53276.19%↑ Y/Y)
Purchases of property,
plant and equipment
$140M
(30.84%↑ Y/Y)
Purchases of marketable
debt securities
$26M
(-98.86%↓ Y/Y)
Purchases of equity
securities
$16M
(-23.81%↓ Y/Y)
Buy us a coffee
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)
Gilead_Sciences_Logo-svg
GILEAD SCIENCES, INC. (GILD)